Enzyme Catalysis

As a CRO that advocates green drug research and development, Medicilon has always been committed to promoting the green upgrading of pharmaceutical processes through technological innovation. Medicilon has already used enzymes in process research and development, and relying on its strong chemical and biological background, Medicilon has established a the Enzyme Catalysis Technology Platform to screen catalytic enzymes for specific reaction types and establish corresponding enzyme libraries to assist process development and production.

Medicilon Enzyme Catalysis Service Platform

01 Chemical Technology Platform
Development of Pharmaceutical Intermediates and APls
Functional Chemical Development
02 Biotechnology Platform
Enzyme Development and Applications
Enzyme Production
03 Quality Technology Platform
Quality and Control Research
Inspection and Testing Services
Medicilon's Enzyme Catalysis Technology Platform includes chemical technology platform, biotechnology platform, and quality technology platform. The platform focuses on the combination of chemical synthesis and biological enzyme catalytic synthesis, the development and application research of biological enzymes, and the R&D and production of pharmaceutical intermediates and APIs using green biotechnology. At the same time, it provides high-end CRO, CDMO services, testing and quality research services to pharmaceutical companies.

Medicilon Enzyme Library

/d/image/20230920/650a7f843c54d.webp

Ketoreductase	D-amino acid dehydrogenase	Transaminase	Nitrile Hydratase	Phenylalanine Lyase	Hydroaminase
Cytochrome Monooxygenase	Threonine Dehydrogenase	Phosphokinase	Epoxide Hydrolase		Nitrilase
Alcohol Oxidase	Formate Dehydrogenase	Nucleoside Phosphorylation (synthesis)	Amidohydrolase		Aldol Condensase
Monoamine Oxidase	Glucose Dehydrogenase		Nitrilase		Other Specialized Enzymes
Nitrile	Lactate			Lactate
Reductase	Dehydrogenase			Dehydrogenase
Nitroreductase	Phenylalanine Dehydrogenase
Imine Reductase	Ammonia Dehydrogenase

At present, Medicilon has successfully established dozens of major biological enzyme libraries, such as ketoreductase, ester hydrolase, imine reductase, nitroreductase, cyclooxygenase, amide hydrolase, for providing suitable biocatalytic solutions for various chemical transformations. These integrated enzymatic services reduce costs, shorten time, and improve quality. With the implementation of a large amount of projects, Medicilon enzyme library is also continuing to be optimized and expanded. Medicilon will also carry out research on immobilized enzymes and coenzymes.

Medicilon’s R&D capabilities in the field of synthetic biology

With the continuous advancement of synthetic biology technology, more and more enzymes with specific catalytic functions are used as biocatalysts to achieve reactions that are difficult to achieve with chemical catalysts, and can be used as catalytic components to build functional modules of synthetic biology. Medicilon has already established a presence in the field of synthetic biology. Through the assembly of different enzyme components, Medicilon has made breakthroughs in the design of synthetic routes for many target molecules and can provide a variety of services:
Molecule and Strain ConstructionStrain Delection and DomesticationEnzyme Co-ExpressionMulti-Enzyme CatalysisBiocatalysisProtein ModificationFermentation MetabolismProtein PurificationFermentation OptimizationEnzyme Immobilization
In the future, Medicilon, as a one-stop biopharmaceutical preclinical R&D service platform, will continue to explore and apply more innovative green chemical technologies to achieve more environmentally friendly, safe, efficient and economical process development and production, and create more innovative products for global clients.

What is preclinical testing?

In the process of preclinical testing of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a preclinical research phase followed, before which, as described above, the potential toxicity of the compou

阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati

阅读全文

Shanghai Medicilon Inc.

搜索此博客